Prognostic factors and efficacy of GDP-R therapy in refractory/relapsed diffuse large B-cell lymphomas not eligible for high-dose therapy

Abstract

Aim: The main aim of the present study was to evaluate the overall survival (OS) and time to treatment failure (TTF) in a cohort of relapsed/refractory diffuse large B-cell lymphomas (DLBCLs) not eligible for high-dose therapy (HDT) treated with gemcitabine in association with dexamethasone, cisplatin and rituximab (GDP-R) protocol. The secondary aim was to identify the prognostic factors impacting OS and TTF.

Methods: The authors retrospectively analyzed 45 patients with refractory/relapsed DLBCLs treated with GDP-R.

Results: Overall response rate (ORR) was 48.8%; complete response 15/45 (33.3%), partial response 7/45 (15.5%). Response was influenced by the number of previous therapies administered and International Prognostic Index (IPI) value. Although no significant impact occurred with regard to OS, patients pre-treated with 2 or < 2 chemotherapeutic regimens had better ORR (P = 0.014) and a longer TTF (P = 0.029 in multivariate Cox model). IPI value also influenced TTF. Patients with < 2 IPI value had significantly more prolonged TTF than the other ones (P = 0.048 in multivariate Cox model). Treatment was well-tolerated, with the majority of patients treated on out-patient modality. GDP-R regimen represents a valid treatment for aggressive relapsed/refractory B-cell lymphoma not eligible for HDT thanks to its efficacy and good toxic profile.

Conclusion: The number of previous chemotherapeutic regimens and IPI value select those who benefit more from this treatment.

Keywords

Cisplatin / dexhametazone / GDP / gemcitabine / relapsed/refractory diffuse large B-cell lymphomas

References

[1] Armitage JO.A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma..Blood1997;89:3909-18

[2] Groves FD,Travis LB.Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995..J Natl Cancer Inst2000;92:1240-51

[3] Gisselbrecht C,Mounier N,Linch DC,Bosly A,Shpilberg O,Ma D,Moskowitz CH.Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era..J Clin Oncol2010;28:4184-90 PMCID:PMC3664033

[4] Sweetenham JW.ESHAP chemotherapy for relapsed/refractory non-Hodgkin's lymphoma..J Clin Oncol1994;12:2766

[5] Bernell P.Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma..Br J Haematol1998;101:203-4

[6] Fossa A,Hiddemann W,Niederle N,Bonadonna G,Nowrousian MR.Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma..J Clin Oncol1999;17:3786-92

[7] Santoro A,Devizzi L,Bonfante V,Fiedler F,Benoehr C,Bonadonna G.Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study..J Clin Oncol2000;18:2615-9

[8] Savage DG,Tighe M,Oster MW,Ruiz J,Keohan ML,Johnson SA.Gemcitabine for relapsed or resistant lymphoma..Ann Oncol2000;11:595-7

[9] Crump M,Couban S,Marcellus D,Imrie K,Adams G,Paul N,Iglesias J.Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)..Cancer2004;101:1835-42

[10] Cheson BD,Coiffler B,Fisher RI,Lister TA,Grillo-López A,Cabanillas F,Hiddemann W,Harris NL,Carter W,Canellos GP.Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma..J Clin Oncol1999;17:1244

[11] Martelli M,Agostinelli C,Pfreundschuh M.Diffuse large B-cell lymphoma..Crit Rev Oncol Hematol2013;87:146-71

[12] Hou Y,Ba Y.Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma..Med Oncol2012;29:2409-16

[13] Fan Y,Luo LH.Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's lymphoma: a report of 24 cases..Ai Zheng2008;27:1222-5